세계 무좀 치료제 시장 – 2023-2030

Global Athlete′s Foot Drugs Market - 2023-2030

상품코드PH6769
발행기관DataM Intelligence
발행일2023.09.06
페이지 수195 Pages
포맷PDF + EXCEL
커버리지Global

6,525,00011,775,000

보고서 요약(국문)

개요
전 세계 무좀 치료제 시장은 2022년 12억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 7.8%의 성장률을 보이며 2030년에는 21억 달러에 이를 것으로 예상됩니다. 스포츠 및 신체 활동 참여 증가와 같은 활동적인 라이프스타일로의 전환 추세로 인해 곰팡이가 번식하기 쉬운 공중 샤워 시설에 노출될 위험이 높아지면서 전 세계 무좀 치료제 시장 성장을 주도할 것으로 전망됩니다.
전 세계 무좀 치료제 시장은 최근 몇 년간 크게 성장했으며, 이러한 상승세는 지속될 것으로 예상됩니다. 천연 및 유기농 치료법에 대한 소비자 선호도 증가로 인한 허브 항진균 제품 개발 등 여러 가지 중요한 추세가 시장을 변화시키고 있습니다.
또한, 곰팡이 감염 및 당뇨병과 같은 감염성 질환의 유병률 증가, 발 건강 및 위생에 대한 인식 제고, 그리고 일반의약품(OTC)의 접근성 향상 등이 무좀 치료제 시장 규모 확대를 견인하고 있습니다. 북미 지역의 무좀 치료제 수요 증가 요인으로는 질병에 대한 연구 활동 증가와 양질의 의료 전문가 접근성으로 인한 잘 구축된 의료 인프라 등이 있습니다. 노바티스(Novartis AG), 바이엘(Bayer AG), 비브케어 파마(Vibcare Pharma Pvt. Ltd.) 등 주요 경쟁 업체들이 시장에서 활발하게 활동하고 있습니다.
시장 동향
당뇨병 환자 증가가 무좀 치료제 시장 성장을 견인할 전망
전 세계적으로 당뇨병 환자 수가 증가함에 따라 전 세계 무좀 치료제 시장이 크게 성장할 것으로 예상됩니다. 당뇨병은 체내 혈당 수치를 높이는 만성 대사 질환으로, 면역 체계를 약화시키고 혈액 순환을 저해하며 신경병증을 유발하여 감염 위험을 높이고 신속한 치료를 필요로 합니다.
예를 들어, 세계보건기구(WHO)의 2023년 보고서에 따르면 전 세계적으로 약 4억 2,200만 명이 당뇨병을 앓고 있으며, 대부분의 환자는 저소득 및 중소득 국가에서 발생하고 있으며, 이로 인해 150만 명이 사망했습니다. 무좀은 피부 건조, 갈라짐, 감각 저하를 유발하며, 당뇨병 환자의 경우 질병에 더 취약하고 재발할 가능성도 높습니다. 따라서 당뇨병 유병률 증가로 인해 당뇨병 환자에게 특화된 무좀 치료제에 대한 수요가 증가하고 있으며, 이에 따라 무좀 치료제 시장도 예측 기간 동안 성장할 것으로 예상됩니다.
비만 유병률 증가가 무좀 치료제 시장 성장을 견인할 전망
전 세계적으로 비만 인구가 증가함에 따라 무좀 치료제 시장이 성장할 것으로 예상됩니다. 비만은 최근 몇 년 동안 주요 문제로 대두되었으며, 발에 심각한 영향을 미칠 수 있습니다. 예를 들어, 세계보건기구(WHO)의 2022년 보고서에 따르면 전 세계적으로 약 10억 명이 비만이며, 이는 성인 6억 5천만 명, 청소년 3억 4천만 명, 어린이 3천 9백만 명을 포함합니다.
발목 염좌, 발의 피로, 물집, 굳은살, 무좀은 비만 환자에게서 흔히 나타나는 발 질환입니다. 과체중인 사람들은 건강한 체중 유지를 위해 필수적인 운동을 하기 어려울 수 있습니다. 게다가 비만은 피부 주름과 해당 부위의 습기 증가를 유발하여 곰팡이 번식에 유리한 환경을 조성합니다. 따라서 비만 인구가 증가함에 따라 발생 가능성이 높은 증상을 관리하고 완화할 수 있는 효과적인 약물에 대한 수요가 크게 증가하고 있으며, 이는 향후 시장 성장을 견인할 것으로 예상됩니다.
노년 인구 증가가 무좀 치료제 시장 성장을 촉진할 전망입니다.
노년 인구 증가는 무좀 치료제 시장 성장을 견인할 것으로 예상됩니다. 고령화로 인해 발 건강이 악화될 가능성이 높아지고, 만성 질환 합병증으로 인해 발 관련 문제가 발생할 가능성도 높아지기 때문입니다. 예를 들어, 세계보건기구(WHO)의 2022년 보고서에 따르면 2030년에는 전 세계 인구 6명 중 1명이 60세 이상이 될 것입니다.
또한 60세 이상 인구는 2020년 10억 명에서 2030년에는 14억 명으로 증가할 것으로 예상됩니다. 이 질환은 여성보다 남성에게 더 흔합니다. 따라서 무좀과 같은 곰팡이 질환으로 인한 불편함과 위험을 완화하고 개인의 취약성을 해결하기 위한 효과적인 약물 치료에 대한 필요성이 증가하고 있습니다.
무좀 치료제의 부작용이 시장 성장을 저해할 것으로 예상됩니다.
무좀 치료제 시장은 약물 부작용과 같은 요인으로 인해 성장이 저해될 것으로 예상됩니다. 무좀 치료제의 가장 흔한 부작용으로는 화끈거림, 따끔거림, 부기, 자극, 발적, 여드름 같은 덩어리, 통증 또는 치료 부위의 각질 탈락 등이 있습니다. 예를 들어, 무좀 치료에 주로 사용되는 항진균제인 케토코나졸은 곰팡이를 죽이는 작용을 하지만 물집, 딱지, 피부 자극 또는 발적과 같은 부작용을 일으킬 수 있습니다.

또한, 무좀 치료에 사용되는 코르티코스테로이드는 무좀 발진에 수 인치 너비의 "양날개" 패턴과 같은 비정상적인 양상을 유발하는 등 심각한 부작용을 일으킬 수 있습니다. 이러한 코르티코스테로이드 크림을 장기간 사용하면 무좀으로 인한 심한 발적과 작열감을 유발할 수 있습니다. 따라서 위와 같은 요인들로 인해 시장은 예측 기간 동안 주요 제약 요인에 직면할 것으로 예상됩니다.
세분화 분석
전 세계 무좀 치료제 시장은 유형, 제품 유형, 약물 종류, 유통 채널 및 지역별로 세분화됩니다.
우수한 효과 덕분에 항진균제 부문은 무좀 치료제 시장 점유율의 약 42.8%를 차지했습니다.
항진균제 부문은 효과, 제형 개발 및 무좀 치료에 대한 우수한 효능으로 인해 무좀 치료제의 1차 치료제이자 선호되는 치료법으로 남아 있어 무좀 치료제 시장을 주도할 것으로 예상됩니다. 가장 일반적으로 사용되는 약물은 클로트리마졸, 미코나졸, 톨나프테이트 또는 테르비나핀, 플루코나졸, 이트라코나졸입니다.
또한 크림, 젤, 스프레이 형태의 일반의약품(OTC)이 출시되면서 항진균제 계열이 선호되고 있습니다. 항진균제인 테르비나핀(라미실 AT)은 특히 효과적인 것으로 입증되었습니다. 클로트리마졸(로트리민 AF)도 좋은 선택입니다. 게다가 신제품 승인은 시장 성장을 촉진할 것입니다. 예를 들어, 2022년 5월 바이엘 컨슈머 헬스 사업부는 인도에서 새롭고 개선된 항진균 치료제인 카네스텐을 출시한다고 발표했습니다. 이 약은 백선, 사타구니 백선, 피부 칸디다증, 무좀, 홍색 반점, 손발톱 무좀 등의 증상을 완화해 줍니다. 따라서 이러한 요인들로 인해 해당 부문은 예측 기간 동안 시장을 주도할 것으로 예상됩니다.

지리적 시장 침투
북미는 무좀의 높은 유병률과 활발한 연구 활동에 힘입어 2022년 시장 점유율 약 39.5%를 차지했습니다.
북미, 특히 미국은 기존 시장 참여 기업들의 존재와 활발한 연구 개발 활동 덕분에 전 세계 무좀 치료제 시장을 주도하고 있습니다. 또한, 임상 시험 건수 증가로 환자 치료 효과 향상을 위한 새로운 치료법들이 개발되고 있습니다.
미국에서 무좀의 원인인 백선과 같은 진균 질환의 유병률 증가가 이 지역의 성장을 견인할 것으로 예상됩니다. 예를 들어, 미국 질병통제예방센터(CDC)의 2023년 자료에 따르면, 백선으로 인한 입원 환자는 690명, 전 세계적으로는 4,981,444명에 달했습니다. 따라서 적절한 치료제를 제공함으로써 입원 건수를 줄이고 환자 치료 효과를 높일 수 있을 것입니다.

또한, 이 지역에서 연구 개발 활동과 임상 시험이 증가함에 따라 치료 옵션이 발전할 것입니다. 예를 들어, 임상 단계의 정밀 피부과 기업인 DermBiont, Inc.는 전장 유전체 시퀀싱(WGS) 및 정량적 중합효소 연쇄 반응(qPCR)을 기반으로 무좀 환자를 대상으로 DBI-001 젤, DBI-002 젤, 그리고 수성 젤의 안전성과 효능을 평가하는 임상 시험을 진행하고 있으며, qPCR과 수산화칼륨(KOH)의 비교도 포함하고 있습니다. 이 시험은 무작위 배정 및 관찰자 맹검 방식으로 진행되며, 수성 젤을 대조군으로 사용합니다. 연구 기간 동안 젤은 약 6~8일 동안 매일 사용될 예정입니다. 따라서, 위에서 언급한 요인들로 인해 이 지역의 시장은 예측 기간 동안 성장할 것으로 예상됩니다.

경쟁 환경
무좀 치료제 시장의 주요 글로벌 업체로는 Novartis AG, Vibcare Pharma Pvt. Ltd. 등이 있습니다. 바이엘 AG, 타로 제약, 글렌마크 제약, 애비게일 헬스케어, 세벨라 제약, ANI 제약, 페리고 등이 그 예입니다.

COVID-19 영향 분석
COVID-19는 면역 체계에 영향을 미치고, COVID-19 치료제(스테로이드 및 기타 약물)가 신체의 항진균 작용을 약화시킬 수 있기 때문에 무좀과 같은 진균 감염 위험을 높일 가능성이 큽니다.
미국 질병통제예방센터(CDC)의 연구에 따르면 COVID-19로 입원한 환자 중 진균 감염을 동반한 경우 사망률이 더 높았습니다. COVID-19와 진균 감염을 모두 가진 환자의 사망률은 팬데믹 기간 동안 48.5%였던 반면, 진균 감염만 있는 환자의 사망률은 12.3%였습니다.

관련된 진균 병원체의 정확한 종류와 관계없이, 코로나19와 진균 감염이 동시에 발생하면 입원 기간이 길어지고, 중환자 치료율이 높아지며, 침습적 기계 환기 사용률이 증가하고, 사망률도 높아집니다. 따라서 코로나19는 무좀 시장에 큰 영향을 미쳤습니다.
유형별
• 발가락 사이 감염
• 모카신형 감염
• 수포형 감염
• 궤양성 감염
제품 유형별
• 국소 크림 및 연고
• 스프레이
• 로션
• 경구용 약물
• 기타
약물 계열별
• 항진균제
• 코르티코스테로이드
• 항생제
• 기타
유통 채널별
• 병원 약국
• 일반 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2022년 6월 20일, 케라살은 출시를 발표했습니다. 새로운 무좀 제품 라인은 무좀을 치료하고 완화할 뿐만 아니라 피부 외관을 개선하고 건강한 발 관리 습관을 지원하는 5가지 효능을 가진 독특한 포뮬러를 특징으로 합니다. 무좀 전용 파우더 스프레이와 실키 클리어 젤을 포함한 새로운 무좀 제품은 브랜드의 발 관리 제품군에 새롭게 추가된 제품입니다.
• 2022년 11월 1일, 자이더스는 중앙 의약품 표준 관리 기구(CDSCO)의 전문가 위원회(SEC)로부터 표재성 피부 진균 감염(체부 백선 및 사타구니 백선) 치료를 위한 항진균제 나프티핀 HCL 2% 크림의 제조 및 판매 승인을 받았습니다.

• 2022년 12월 22일, 시노켐 제약(Synokem Pharmaceutical)은 중앙 의약품 표준 관리 기구(CDSCO)의 전문가 위원회(SEC)로부터 표재성 피부 진균 감염 치료를 위한 항진균제 나프티핀 HCL 크림 2% w/w의 제조 및 판매 승인을 받았습니다.
DMI 의견
전 세계 무좀 치료제 시장은 활동적인 라이프스타일의 증가, 감염성 질환 및 당뇨병의 유병률 증가, 고령화 등의 요인으로 인해 성장세를 보이고 있습니다. 천연 요법에 대한 소비자 선호도 증가와 새로운 치료법 개발은 시장의 도약기를 반영합니다. 반면, 부작용 발생 가능성과 코로나19 팬데믹으로 인한 어려움 또한 간과할 수 없습니다. 시장의 미래는 이러한 어려움을 얼마나 잘 해결하고, 업계가 소비자 요구를 얼마나 효과적으로 충족하며 지속적으로 발전해 나가는지에 달려 있습니다.
이 보고서를 구매해야 하는 이유

• 유형, 제품 유형, 약물 분류, 유통 채널 및 지역별 글로벌 무좀 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 무좀 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 무좀 치료제 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Athlete′s Foot Drugs Market reached US$ 1.2 billion in 2022 and is expected to reach US$ 2.1 billion by 2030 growing with a CAGR of 7.8% during the forecast period 2023-2030. The trend such as the shift towards active lifestyle such as growing participation in sport and physical activities develops the risk of exposure to public showers where fungus can trive, is expected to dominate the global athlete′s foot drugs market.
The global athlete′s foot drugs market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as the growing consumer preference towards natural and organic treatment options that leads to development of herbal antifungal products.
Furthermore, the rising prevalence of infectious disease such as fungal infections and diabetes, growing awareness health and hygiene of foot, moreover availability of OTC products are driving up the athlete′s foot drugs market size. The growing research activities about the disease and presence of establish heathcare infrastructure due to access to quality medical professional are some of the factors in demand from North American regions. With significant competitors like Novartis AG, Bayer AG, Vibcare Pharma Pvt. Ltd., and others actively operating in the market.
Dynamics
The Increasing Prevalence of Diabetic People to Drive the Growth of the Athlete′s Foot Drugs Market
The increasing prevalence of diabetes around the globe is expected to significantly drive the global athlete's foot drugs market. Diabetes is a chronic, metabolic disease that elevates the levels of blood glucose level in body, that leads to weakens the immune system, impairs circulation, and causes neuropathy, elevating the risk of infections and necessitating prompt treatment.
For instance, according to World Health Organization 2023 report, approximately 422 million people around the world are suffering from diabetes and the majority of cases are seen in low-and middle-income countries, that has led to 1.5 million deaths. As during athlete’s foot dryness, cracking, and reduced sensation of skin occurs that leds to more vulnerability of disease having diabtes and can be recurrent too. Thus, as the prevalence of diabetes propel the demand for effective treatment for the people suffering diabetic-specific challenges within the athlete's foot drugs market is expected to drive over the forecast period.
The Rising Prevalence of Obesity will Drive the Athlete′s Foot Drugs Market Growth
The growing prevalence of obese people across the globe is expected to boost the market of athlete’s foot drugs. Obesity has become a major issue in recent years, and it can have severe consequences on feet. For instance, according to World Health Organization 2022 report, approximately 1 billion people globally are obesed that accounts 650 million adults, 340 million adolescents and 39 million children.
Sprained ankles, general foot fatigue, blisters, calluses, and athlete's foot are some of the most common foot disorders in obese patients. Overweight people may find it difficult to exercise, which is essential for keeping a healthy weight. Moreover, obesity frequently causes skin wrinkles and increased moisture in these regions, creating an environment favorable to fungal growth. Thus, as the obesed people population increases, there is major need of effective drugs to manage and alleviate the symtoms that are likely to occur and thereby driving the market over the foreseeable future.
The Growing Geriatric Population will Drive the Athlete′s Foot Drugs Market Growth
The increasing elderly population is expected to drive the athlete’s foot market owing to the factors such as the people age, they are more susceptible to have poor foot health, along with other chronic disease complications that lead to foot related problems. For instance, according to World Health Organization 2022 report, 1 in 6 people in the world will age above 60 years by 2030.
Furthermore, the people aging above 60 will increase from 1 billion in 2020 to 1.4 billion. This disorder is more prevalent in males compared to female population. Thus, there is increase the need for efficient drug treatments to address their individual vulnerabilities and the discomfort and risks associated with fungal diseases such as athlete's foot.
The Side Effects Associated with the Athlete’s Foot Drugs Will Hamper the Growth of the Market
The athlete′s foot drugs market is expected to be hamper owing to the factors such as side effects from the drugs. The most prevalent adverse reactions of athlete's foot medications are burning, stinging, swelling, irritation, redness, pimple-like lumps, soreness, or flaking of the treated area. For instance, Ketoconazole an antifungal drug that works by killing fungi that and is mostly given to treat athlete foot disease has some side effects such as blistering, crusting, irritated or red skin.
Moreover, corticosteroid used to treat athlete foot disease can have major side effects unusual patterns in ringworm rashes, like this “double-edged” pattern that is several inches wide. Long term use of these corticosteroid creams combination may lead to severe redness and burning with ringworm. Thus, owing to the above factors the market is expected to face a major restraint over the forecast period.
Segment Analysis
The global athlete′s foot drugs market is segmented based on type, product type, drug class, distribution channel, and region.
Owing to its Better Effectiveness, the Anti Fungal Segment Accounted for Approximately 42.8% of the Athlete’s Foot Drugs Market Share
The anti fungal segment is poised to dominate the athlete′s foot drugs market as it remains a first-line and preferred medical treatment for athlete′s foot drugs owing to its effectiveness, advancements in formulations, and better efficacy for treating athlete’s foot disorder. The most commonly used drugs are clotrimazole, miconazole, tolnaftate or terbinafine, fluconazole, itraconazole.
Furthermore, the availability of over-the-counter (OTC) drugs in the forms of creams, gels, sprays makes antifungal class a preferred choice. Terbinafine (Lamisil AT), an antifungal, has been demonstrated to be particularly effective. Clotrimazole (Lotrimin AF) is another possibility. Moreover, new product approval will propel the market forward, for instance, in May 2022, Bayer's Consumer Health division announced the launch of the new and improved Canesten anti-fungal treatment solution in India. This medication provides relief from ringworm, jock itch, skin candidiasis, athlete's foot, erythrasma and fungal nail infection. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
Geographical Penetration
North America Accounted for Approximately 39.5% of the Market Share in 2022, Owing to the Prevalence of Athlete’s Foot and Increasing Research Activities
North America, particularly the U.S., dominates the global athlete′s foot drugs market due to its presence of established market players, along with increasing R&D activities. Furthermore, the increasing number of clinical trials led to novel treatments for better patient outcomes.
The rising prevalence of fungal disease such as dermatophytosis due to which athlete’s foot is caused in U.S. is expected to drive the region. For instance, according to Center for Disease Control and Prevention article of 2023, dermatophytosis (ringworm) has resulted with 690 hospitalization, and 4,981,444 in U.S. Thus, this increasing number of hospitalization can be restricted by providing appropriate drug for better health outcomes.
Morover, increasing number of R&D activities and clinical trial in this region will lead to advancements in treatment options. For instance, DermBiont, Inc., a clinical stage precision dermatology company is conducting a clinical trial to evaluate the safety and efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in subjects with tinea pedis based on Whole Genome Sequencing (WGS) and Quantitative Polymerase Chain Reaction (qPCR), and comparison between Quantitative Polymerase Chain Reaction (qPCR) and Potassium Hydroxide (KOH). The trial is randomized and observer-blind, with an Aqueous Gel as a control group. The gels will be used daily for roughly 6-8 days during the study. Thus, owing to the factor stated above, the market in this region is expected to grow over the forecast period.
Competitive Landscape
The major global players in the athlete′s foot drugs market include Novartis AG, Vibcare Pharma Pvt. Ltd., Bayer AG, Taro Pharmaceutical Industries Ltd, GLENMARK PHARMACEUTICALS LTD., Abigail Healthcare Pharmaceutical, Sebela Pharmaceuticals, ANI Pharmaceuticals, Inc. and Perrigo Company plc among others.
COVID-19 Impact Analysis
COVID-19 most likely raises the risk of fungal infections such as athlete’s foot due to its effect on the immune system and the fact that COVID-19 therapies (such as steroids and other medicines) might decrease the body's defenses against fungus.
Research conducted by the Centers for Disease Control and Prevention discovered that patients brought to the hospital with covid-19 were more likely to die if they also had a fungal infection. Patients with covid-19 and a fungal infection died at a rate of 48.5% during the pandemic, compared to 12.3% in patients with only fungal infections.
Regardless of the precise fungal pathogens involved, dual covid-19 and fungal infections resulted in longer hospital admissions, greater rates of critical care treatment, more usage of invasive mechanical ventilation, and more mortality. Thus, Covid-19 has created a major impact on athlete’s foot market.
By Type
• Toe Web Infection
• Moccasin-type Infection
• Vesicular-type Infection
• Ulcerative Infection
By Product Type
• Topical Creams and Ointments
• Sprays
• Lotions
• Oral Medications
• Others
By Drug Class
• Antifungal Agents
• Corticosteroid
• Antibiotics
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On June 20, 2022, Kerasal announced the launch of a new Athlete's Foot product line that includes a unique formula with 5-in-1 advantages to not only treat and heal most athlete's foot but also improve skin appearance and support a healthy footcare routine. The new Athlete's Foot products, which include the Athlete's Foot Invisible Powder Spray and Athlete's Foot Silky Clear Gel, are the latest additions to the brand's foot care range.
• On November 1, 2022, Zydus received approval from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organization (CDSCO) to manufacture and market the antifungal drug Naftifine HCL 2% Cream in the country for the treatment of superficial fungal infections of the skin (Tinea corporis and Tinea cruris).
• On December 22, 2022, Synokem Pharmaceutical has received approval from the Central Drug Standard Control Organization's (CDSCO) Subject Expert Committee (SEC) to manufacture and market the antifungal drug Naftifine HCL Cream 2% w/w for the treatment of superficial fungal infection of the skin.
DMI Opinion
The global athlete's foot drugs market appears to be on the rise, owing to factors such as a change toward an active lifestyle, the prevalence of infectious diseases and diabetes, and an aging population. Consumer preferences for natural remedies and the development of new treatment choices reflect the market's breakthrough period. The possibility of side effects and the challenges posed by the COVID-19 pandemic, on the other hand, should not be neglected. The market's outcome will be influenced by how well these difficulties are addressed, as well as how effectively the industry continues to develop and meet consumer needs.
Why Purchase the Report?
• To visualize the global athlete′s foot drugs market segmentation based on type, product type, drug class, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of athlete′s foot drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global athlete′s foot drugs market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Product Type
3.3. Snippet by Drug Class
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Prevalence of Diabetic People
4.1.1.2. The Rising Prevalence of Obesity
4.1.1.3. The Growing Geriatric Population
4.1.2. Restraints
4.1.2.1. The Side Effects Associated with the Athlete’s Foot Drugs
4.1.3. Opportunity
4.1.3.1. Increasing Demand for Personalized Medicine
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Toe Web Infection*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Moccasin-type Infection
7.4. Vesicular-type Infection
7.5. Ulcerative Infection
8. By Product Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.1.2. Market Attractiveness Index, By Product Type
8.2. Topical Creams and Ointments*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Sprays
8.4. Lotions
8.5. Oral Medications
8.6. Others
9. By Drug Class
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Antifungal Agents*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Corticosteroid
9.4. Antibiotics
9.5. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Novartis AG*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Vibcare Pharma Pvt. Ltd.
13.3. Bayer AG
13.4. Taro Pharmaceutical Industries Ltd
13.5. GLENMARK PHARMACEUTICALS LTD.
13.6. Abigail Healthcare Pharmaceutical
13.7. Sebela Pharmaceuticals
13.8. ANI Pharmaceuticals, Inc.
13.9. Perrigo Company plc
13.10. Xiromed
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Novartis AG, 4. Key Developments, Vibcare Pharma Pvt. Ltd., Bayer AG, Taro Pharmaceutical Industries Ltd, GLENMARK PHARMACEUTICALS LTD., Abigail Healthcare Pharmaceutical, Sebela Pharmaceuticals, ANI Pharmaceuticals, Inc., Perrigo Company plc, Xiromed

표 목록 (Tables)

List of Tables

Table 1 Global Athlete′s Foot Drugs Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Athlete′s Foot Drugs Market Value, By Product Type, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Athlete′s Foot Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Athlete′s Foot Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Athlete′s Foot Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Athlete′s Foot Drugs Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Athlete′s Foot Drugs Market Value, By Type, 2021-2030 (US$ Billion)

Table 8 Global Athlete′s Foot Drugs Market Value, By Product Type, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Athlete′s Foot Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 10 Global Athlete′s Foot Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Athlete′s Foot Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 12 Global Athlete′s Foot Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Athlete′s Foot Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 14 Global Athlete′s Foot Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Athlete′s Foot Drugs Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Athlete′s Foot Drugs Market Value, By Type, 2021-2030 (US$ Billion)

Table 17 North America Athlete′s Foot Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 18 North America Athlete′s Foot Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 19 North America Athlete′s Foot Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 North America Athlete′s Foot Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Athlete′s Foot Drugs Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 South America Athlete′s Foot Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 23 South America Athlete′s Foot Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 24 South America Athlete′s Foot Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 25 South America Athlete′s Foot Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Athlete′s Foot Drugs Market Value, By Type, 2021-2030 (US$ Billion)

Table 27 Europe Athlete′s Foot Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 28 Europe Athlete′s Foot Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 29 Europe Athlete′s Foot Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 30 Europe Athlete′s Foot Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Athlete′s Foot Drugs Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Athlete′s Foot Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Athlete′s Foot Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Athlete′s Foot Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Athlete′s Foot Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Athlete′s Foot Drugs Market Value, By Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Athlete′s Foot Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Athlete′s Foot Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Athlete′s Foot Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 40 Novartis AG: Overview

Table 41 Novartis AG: Product Portfolio

Table 42 Novartis AG: Key Developments

Table 43 Vibcare Pharma Pvt. Ltd.: Overview

Table 44 Vibcare Pharma Pvt. Ltd.: Product Portfolio

Table 45 Vibcare Pharma Pvt. Ltd.: Key Developments

Table 46 Bayer AG: Overview

Table 47 Bayer AG: Product Portfolio

Table 48 Bayer AG: Key Developments

Table 49 Taro Pharmaceutical Industries Ltd: Overview

Table 50 Taro Pharmaceutical Industries Ltd: Product Portfolio

Table 51 Taro Pharmaceutical Industries Ltd: Key Developments

Table 52 GLENMARK PHARMACEUTICALS LTD.: Overview

Table 53 GLENMARK PHARMACEUTICALS LTD.: Product Portfolio

Table 54 GLENMARK PHARMACEUTICALS LTD.: Key Developments

Table 55 Abigail Healthcare Pharmaceutical: Overview

Table 56 Abigail Healthcare Pharmaceutical: Product Portfolio

Table 57 Abigail Healthcare Pharmaceutical: Key Developments

Table 58 Sebela Pharmaceuticals: Overview

Table 59 Sebela Pharmaceuticals: Product Portfolio

Table 60 Sebela Pharmaceuticals: Key Developments

Table 61 ANI Pharmaceuticals, Inc.: Overview

Table 62 ANI Pharmaceuticals, Inc.: Product Portfolio

Table 63 ANI Pharmaceuticals, Inc.: Key Developments

Table 64 Perrigo Company plc: Overview

Table 65 Perrigo Company plc: Product Portfolio

Table 66 Perrigo Company plc: Key Developments

Table 67 Xiromed: Overview

Table 68 Xiromed: Product Portfolio

Table 69 Xiromed: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Athlete′s Foot Drugs Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Athlete′s Foot Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 4 Global Athlete′s Foot Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 5 Global Athlete′s Foot Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Athlete′s Foot Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Athlete′s Foot Drugs Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Toe Web Infection Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 9 Moccasin-type Infection Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 10 Vesicular-type Infection Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 11 Ulcerative Infection Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 12 Global Athlete′s Foot Drugs Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure 13 Topical Creams and Ointments Product Type in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 14 Sprays Product Type in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 15 Lotions Product Type in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 16 Oral Medications Product Type in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 17 Others Product Type in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 18 Global Athlete′s Foot Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 19 Antifungal Agents Drug Class in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 20 Corticosteroid Drug Class in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 21 Antibiotics Drug Class in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 22 Others Drug Class in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 23 Global Athlete′s Foot Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 24 Hospital Pharmacies Distribution Channel in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 25 Retail Pharmacies Distribution Channel in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 26 Online Pharmacies Distribution Channel in Global Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 27 Global Athlete′s Foot Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 29 Asia-Pacific Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 30 Europe Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 31 South America Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 32 Middle East and Africa Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 33 North America Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 34 North America Athlete′s Foot Drugs Market Share, By Type, 2022 & 2030 (%)

Figure 35 North America Athlete′s Foot Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 36 North America Athlete′s Foot Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 37 North America Athlete′s Foot Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 38 North America Athlete′s Foot Drugs Market Share, By 0, 2022 & 2030 (%)

Figure 39 North America Athlete′s Foot Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 40 South America Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 41 South America Athlete′s Foot Drugs Market Share, By Type, 2022 & 2030 (%)

Figure 42 South America Athlete′s Foot Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 43 South America Athlete′s Foot Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 44 South America Athlete′s Foot Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 South America Athlete′s Foot Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 46 Europe Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 47 Europe Athlete′s Foot Drugs Market Share, By Type, 2022 & 2030 (%)

Figure 48 Europe Athlete′s Foot Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 49 Europe Athlete′s Foot Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 50 Europe Athlete′s Foot Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 51 Europe Athlete′s Foot Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 52 Asia-Pacific Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 53 Asia-Pacific Athlete′s Foot Drugs Market Share, By Type, 2022 & 2030 (%)

Figure 54 Asia-Pacific Athlete′s Foot Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 55 Asia-Pacific Athlete′s Foot Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 56 Asia-Pacific Athlete′s Foot Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 57 Asia-Pacific Athlete′s Foot Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 58 Middle East & Africa Athlete′s Foot Drugs Market Value, 2021-2030 (US$ Billion)

Figure 59 Middle East & Africa Athlete′s Foot Drugs Market Share, By Type, 2022 & 2030 (%)

Figure 60 Middle East & Africa Athlete′s Foot Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 61 Middle East & Africa Athlete′s Foot Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 62 Middle East & Africa Athlete′s Foot Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 63 Novartis AG: Financials

Figure 64 Vibcare Pharma Pvt. Ltd.: Financials

Figure 65 Bayer AG: Financials

Figure 66 Taro Pharmaceutical Industries Ltd: Financials

Figure 67 GLENMARK PHARMACEUTICALS LTD.: Financials

Figure 68 Abigail Healthcare Pharmaceutical: Financials

Figure 69 Sebela Pharmaceuticals: Financials

Figure 70 ANI Pharmaceuticals, Inc.: Financials

Figure 71 Perrigo Company plc: Financials

Figure 72 Xiromed: Financials